Masahiro Goto Selected Research

Squamous Cell Carcinoma of Head and Neck

10/2020	Two-year follow-up of a randomized phase III clinical trial of nivolumab vs. the investigator's choice of therapy in the Asian population for recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141).
10/2017	A randomized, open-label, Phase III clinical trial of nivolumab vs. therapy of investigator's choice in recurrent squamous cell carcinoma of the head and neck: A subanalysis of Asian patients versus the global population in checkmate 141.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Masahiro Goto Research Topics

Disease

42	Neoplasms (Cancer) 11/2023 - 04/2002
34	Stomach Neoplasms (Stomach Cancer) 04/2024 - 01/2005
19	Colorectal Neoplasms (Colorectal Cancer) 01/2024 - 01/2013
10	Neoplasm Metastasis (Metastasis) 11/2023 - 04/2006
6	Disease Progression 10/2021 - 01/2009
5	Adenocarcinoma 03/2023 - 02/2014
5	Hypersensitivity (Allergy) 08/2020 - 01/2018
5	Seasonal Allergic Rhinitis (Hay Fever) 03/2020 - 12/2015
4	Neutropenia 09/2023 - 10/2013
4	Gastrointestinal Neoplasms (Gastrointestinal Cancer) 01/2023 - 10/2011
4	Hepatocellular Carcinoma (Hepatoma) 06/2022 - 11/2016
4	Nausea 03/2021 - 01/2006
3	Esophageal Neoplasms (Esophageal Cancer) 04/2024 - 06/2003
3	Infections 03/2024 - 11/2004
3	Mycoses (Diseases, Fungus) 03/2024 - 01/2022
3	Febrile Neutropenia 09/2023 - 01/2015
3	Diarrhea 01/2023 - 02/2018
3	Ascites 01/2022 - 09/2012
3	Pancreatic Neoplasms (Pancreatic Cancer) 11/2021 - 01/2015
3	Vomiting 03/2021 - 01/2006
3	Dehydration (Water Stress) 08/2020 - 01/2009
2	Out-of-Hospital Cardiac Arrest 01/2024 - 01/2023
2	Hemorrhage 01/2024 - 02/2021
2	COVID-19 11/2022 - 01/2021
2	Squamous Cell Carcinoma of Head and Neck 10/2020 - 10/2017
2	Carcinoma (Carcinomatosis) 01/2020 - 04/2002
2	Mucocutaneous Lymph Node Syndrome (Kawasaki Disease) 07/2015 - 01/2015
2	Anorexia 10/2013 - 08/2002
2	Hypertension (High Blood Pressure) 09/2013 - 10/2011
1	Lymphatic Metastasis 01/2024
1	Brain Neoplasms (Brain Tumor) 11/2023
1	Brain Stem Infarctions (Weber Syndrome) 06/2023

Drug/Important Bio-Agent (IBA)

15	Oxaliplatin (Eloxatin)FDA LinkGeneric 04/2024 - 01/2013
12	Irinotecan (Camptosar)FDA LinkGeneric 09/2023 - 01/2007
9	Cisplatin (Platino)FDA LinkGeneric 09/2023 - 09/2012
9	AntigensIBA 03/2023 - 12/2015
8	Fluorouracil (Carac)FDA LinkGeneric 05/2022 - 09/2012
8	Paclitaxel (Taxol)FDA LinkGeneric 10/2021 - 04/2006
7	Proteins (Proteins, Gene)FDA Link 11/2022 - 01/2018
6	Capecitabine (Xeloda)FDA Link 11/2023 - 01/2020
6	Panitumumab (Vectibix)FDA Link 01/2023 - 06/2019
6	Bevacizumab (Avastin)FDA Link 09/2022 - 01/2013
6	Peptides (Polypeptides)IBA 01/2019 - 01/2015
5	pembrolizumabIBA 04/2024 - 01/2022
5	VaccinesIBA 01/2023 - 05/2019
5	Leucovorin (Folinic Acid)FDA Link 03/2021 - 09/2012
4	Biomarkers (Surrogate Marker)IBA 04/2024 - 01/2020
4	Dexamethasone (Maxidex)FDA LinkGeneric 01/2023 - 01/2006
4	Ionic LiquidsIBA 01/2022 - 01/2018
4	NivolumabIBA 01/2022 - 10/2017
3	Trastuzumab (Herceptin)FDA Link 04/2024 - 11/2019
3	Docetaxel (Taxotere)FDA Link 01/2024 - 07/2022
3	B7-H1 AntigenIBA 09/2023 - 10/2022
3	Circulating Tumor DNAIBA 01/2023 - 12/2020
3	LipidsIBA 09/2022 - 01/2015
3	S-1 plus cisplatinIBA 10/2021 - 04/2014
3	Cancer VaccinesIBA 01/2020 - 01/2018
3	T-Lymphocyte Epitopes (Epitopes, T Lymphocyte)IBA 08/2017 - 12/2015
3	Immunoglobulin E (IgE)IBA 08/2017 - 12/2015
3	Adrenocorticotropic Hormone (ACTH)FDA Link 07/2016 - 01/2007
3	Prednisolone (Predate)FDA LinkGeneric 01/2016 - 01/2015
3	EnzymesIBA 12/2015 - 01/2007
2	Amphotericin B (Amphotericin)FDA LinkGeneric 03/2024 - 01/2022
2	AcidsIBA 01/2023 - 09/2012
2	Cetuximab (Erbitux)FDA Link 09/2022 - 01/2020
2	RamucirumabIBA 07/2022 - 11/2020
2	PlatinumIBA 05/2022 - 10/2017
2	Cytotoxins (Cytolysins)IBA 03/2022 - 05/2021
2	regorafenibIBA 01/2022 - 10/2021
2	AntibodiesIBA 01/2022 - 01/2022
2	folfirinoxIBA 11/2021 - 01/2015
2	CytokinesIBA 08/2021 - 08/2017
2	trifluridine tipiracil drug combinationIBA 07/2021 - 12/2018
2	AntiemeticsIBA 03/2021 - 01/2006
2	resiquimodIBA 05/2019 - 01/2018
2	Capsules (Microcapsules)IBA 02/2019 - 02/2018
2	130-nm albumin-bound paclitaxelIBA 01/2019 - 07/2014
2	HydrogelsIBA 01/2019 - 11/2016
2	GlucocorticoidsIBA 07/2016 - 01/2009
2	Hydrocortisone (Cortisol)FDA LinkGeneric 07/2016 - 07/2015
2	Intravenous Immunoglobulins (IVIG)FDA Link 07/2015 - 01/2015
2	doxifluridineIBA 03/2008 - 04/2006
1	liposomal amphotericin B FDA Link 03/2024
1	Carcinoembryonic AntigenIBA 01/2024
1	Angiogenesis InhibitorsIBA 01/2024
1	S 1 (combination)IBA 09/2023
1	NanovaccinesIBA 03/2023

Therapy/Procedure

37	Drug Therapy (Chemotherapy) 04/2024 - 01/2005
31	Therapeutics 11/2023 - 01/2006
11	Immunotherapy 01/2022 - 12/2015
7	Gastrectomy 01/2024 - 04/2014
7	Combination Drug Therapy (Combination Chemotherapy) 05/2022 - 04/2006
5	Adjuvant Chemotherapy 01/2024 - 04/2014
5	Hepatectomy 06/2022 - 10/2019
3	Cardiopulmonary Resuscitation (CPR) 01/2024 - 01/2023
3	Premedication 01/2023 - 07/2014
2	Blood Transfusion (Blood Transfusions) 01/2024 - 02/2021
2	Neoadjuvant Therapy 03/2021 - 01/2020
2	Chemoradiotherapy 06/2020 - 06/2003
1	Length of Stay 01/2024